期刊： PHARMACOGENETICS AND GENOMICS, 2022; 32 (2)
Objective Genetic alterations in CDKN2A tumor suppressor gene on chromosome 9p21 confer a predisposition to childhood acute lymphoblastic leukemia (AL......
期刊： PHARMACOGENETICS AND GENOMICS, 2022; 32 (7)
Objective To assess the impact of cytochrome P450 (CYP) 2C19 polymorphisms on the clinical efficacy and safety of voriconazole. Methods We systematica......
期刊： PHARMACOGENETICS AND GENOMICS, 2022; 32 (4)
Oral squamous cell carcinoma (OSCC) is one of the most common malignant tumors worldwide and there are few crucial regulators and druggable targets fo......
期刊： PHARMACOGENETICS AND GENOMICS, 2022; 32 (7)
Tacrolimus has been widely used in membranous nephropathy in recent years. The drug interactions of the coadministration of tacrolimus with omeprazole......
期刊： PHARMACOGENETICS AND GENOMICS, 2022; 32 (1)
Objectives Opioid dependence is currently one of the most serious problems affecting the social norms and public health system. Methadone maintenance ......
期刊： PHARMACOGENETICS AND GENOMICS, 2022; 32 (2)
Metformin is the first-choice oral anti-hyperglycemic drug for type 2 diabetes mellitus (T2DM) patients. There are controversies about the association......
期刊： PHARMACOGENETICS AND GENOMICS, 2022; 32 (4)
Objectives Voriconazole is the most commonly used antifungal agent in clinical application. Previous studies suggested that voriconazole was extensive......
期刊： PHARMACOGENETICS AND GENOMICS, 2022; 32 (4)
Objectives Genetic variation has been considered a major contributor to the high variability in the response to dual antiplatelet therapy in patients ......
期刊： PHARMACOGENETICS AND GENOMICS, 2022; 32 (7)
Objective Gut dysbiosis contributes to multiple autoimmune diseases, including ankylosing spondylitis. which is commonly treated with tumor necrosis f......
期刊： PHARMACOGENETICS AND GENOMICS, 2021; 31 (8)
Objectives Genome-wide analyses of antidepressant response have suggested that genes initially associated with risk for schizophrenia may also serve a......
期刊： PHARMACOGENETICS AND GENOMICS, 2021; 31 (4)
Background Lung cancer is the leading cause of cancer-related mortality worldwide and CMTM8 is a potential tumor suppressor gene, which is down-regula......
期刊： PHARMACOGENETICS AND GENOMICS, 2019; 29 (4)
Objective Antituberculosis (anti-TB) drug-induced hepatotoxicity (ATDH) is a serious adverse drug reaction, and its pathogenic mechanism has not been ......
期刊： PHARMACOGENETICS AND GENOMICS, 2018; 28 (12)
Objective The aim of this study was to determine the impact of the SLCO1B1, apolipoprotein E (ApoE), and CYP2C9 genotypes on the lipid-lowering effica......
期刊： PHARMACOGENETICS AND GENOMICS, 2018; 28 (5)
BackgroundHyperuricemia and gout have become increasingly prevalent in China. Allopurinol is an effective urate-lowering therapy, but it has severe si......
